Hemoglobin Concentration in Patients With an Acute Respiratory Distress Syndrome
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03871166|
Recruitment Status : Recruiting
First Posted : March 12, 2019
Last Update Posted : October 3, 2019
|Condition or disease||Intervention/treatment|
|ARDS, Human||Other: Blood transfusion|
Transfusion of packed red blood cells is a common procedure in critically ill patients. In recent years it has been shown that for many patient populations a restrictive transfusion strategy is not inferior compared to a liberal transfusion strategy with regard to overall outcome.
So far it is unclear whether patients with an ARDS should receive blood transfusions according to a restrictive or liberal transfusion strategy. Besides pulmonary gar exchange and cardiac output, the hemoglobin concentration is an important determinant for oxygen delivery.
The aim of this retrospective observational study is to analyze if low levels of hemoglobin/a restrictive transfusion strategy and are associated with a different mortality compared to higher levels of hemoglobin/a liberal transfusion strategy in patients with an ARDS.
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Hemoglobin Concentration in Patients With an Acute Respiratory Distress Syndrome|
|Actual Study Start Date :||August 1, 2018|
|Estimated Primary Completion Date :||October 1, 2019|
|Estimated Study Completion Date :||December 1, 2019|
- Other: Blood transfusion
Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.
Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.
[Time Frame: 01/2007 - 12/2018]
- Mortality [ Time Frame: 01/2007 - 12/2018 ]Mortality of patients with ARDS at 28 days according to transfusion threshold
- Failure-free days composites [ Time Frame: 01/2007 - 12/2018 ]Failure-free days composites according to transfusion threshold
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03871166
|Contact: Jan A Graw, MDfirstname.lastname@example.org|
|Contact: Oliver Hunsicker, MDemail@example.com|
|Department of Anesthesiology and Operative Intensive Care Medicine Campus Virchow-Klinikum||Recruiting|
|Berlin, Germany, 13353|
|Contact: Oliver Hunsicker, MD +4930450551001 Oliver.firstname.lastname@example.org|
|Principal Investigator:||Jan A Graw, MD||Charite University, Berlin, Germany|